Agios Pharmaceuticals Income Statement 2025-2010 | AGIO

Brief overview of revenue and earnings at Agios Pharmaceuticals

The overview follows changes across a five-year period. According to figures from Agios Pharmaceuticals, revenue changed from $203 million to $54 million over five years. Across the full period, sales moved by −73.4%; the average annual rate was −23.3%. The negative rate indicates weakening core operations.

Gross profit was $200 million at the start and $47.7 million at the end of the period (−76.2%). Costs absorbed a larger share of revenue over the period. Gross profit as a share of revenue changed from 98.6% to 88.3%. The business retained less gross profit from each unit of revenue.

Over the period, EBITDA shifted from −$327 million to −$467 million, a change of −43%. The operating result outpaced sales and points to improving efficiency. EBITDA margin moved from −160.7% to −864.2%. The business retained less EBITDA from each unit of revenue.

Net income moved from −$327 million at the start to −$413 million at the end. Larger losses indicate rising pressure on the business.

Market value was $3 billion at the start and $1.6 billion at the end. Lower capitalization reflects weaker investor expectations.

Overall conclusion

The financial trajectory is weak and requires a cautious interpretation. The overall view is constrained by a weaker final result, pressure on operating profitability and declining capitalization. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.